MAPS Therapy Educational Program in Iceland
MDMA-assisted psychotherapy for PTSD
November 4th – 11th 2023
Hugvíkkandi (The Icelandic Psychedelic Society), Telous (Haraldur Erlendsson consultant psychiatrist) in collaboration with Silfurberg* investment company (Friðrik Steinn Kristjánsson) and MAPS (The Multidisciplinary Association for Psychedelic Studies) are proud to announce the first MAPS educational program in Iceland in November 2023.
This is held with the support of Network for Psychedelic Therapy and Medicine (Denmark), Norsk Psykedelisk Vitenskab, Psykologvirke, Nordic Psychedelic Science (Norway), Nätverket for Psykedelisk Vetenskab (Sweden) and Finnish Association for Psychedelic Research (Finland).
Investigational MDMA-Assisted Therapy for PTSD
MDMA-assisted therapy for PTSD is an investigational treatment not yet approved for use outside of research. MAPS (the Multidisciplinary Association for Psychedelic Studies) and its public benefit corporation (MAPS PBC) are conducting international clinical trials investigating MDMA assisted therapy for PTSD. After preliminary studies demonstrated the safety and efficacy in the treatment of PTSD, the Food and Drug Administration (FDA) granted Breakthrough Therapy designation for MDMA. One Phase 3 trial has been completed, demonstrating that 67% of participants in the MDMA group no longer qualified for a PTSD diagnosis two months post-treatment, compared to 32% of participants in the placebo group. A second Phase 3 trial has been completed, and study results will be used to support an application for FDA approval for MDMA assisted therapy for PTSD.
As stated previously, one Phase 3 trial for MDMA-Assisted Therapy (MDMA-AT) in the US has been completed and there is interest in learning about this modality of therapy in other countries. Bringing education on MDMA-AT research to the Nordic countries is an important and exciting task and we believe that creating a Nordic community of therapists educated in its concepts will be a big step forward for our region. We hope to see a community of therapists actively getting involved in educating the public and other professionals about MDMA-AT and work to create possibilities for new research, compassionate use programs and the advancement of the psychedelic-assisted therapy field. Therefore we are offering this unique opportunity to participate in this MAPS education program on MDMA-AT and to join a community of like-minded individuals who are passionate about learning about MDMA-AT clinical research. With the generous support of MAPS and Silfurberg* investment company (Friðrik Steinn Kristjánsson) we are able to offer the educational at a price that is much more affordable than having to go to the States. At the same time, you will become a part of a Nordic community of therapists who have participated in this MAPS education program, where we will be able to support each other in creating opportunities for more research and advocacy in MDMA-AT research in the coming years.
Last updated on August 3rd 2023